Published in Mol Pharm on July 12, 2013
Multifaceted applications of bile salts in pharmacy: an emphasis on nanomedicine. Int J Nanomedicine (2015) 0.76
The Influence of Chitosan on the Oral Bioavailability of Acyclovir--a Comparative Bioavailability Study in Humans. Pharm Res (2015) 0.75
Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm (2004) 2.63
A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol Pharm (2006) 2.07
A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol (2002) 1.85
Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res (2002) 1.74
Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles. J Control Release (2003) 1.72
Neuroglobin and cytoglobin in search of their role in the vertebrate globin family. J Inorg Biochem (2005) 1.71
A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm (2011) 1.61
The use of BDDCS in classifying the permeability of marketed drugs. Pharm Res (2008) 1.57
Cytoglobin is a respiratory protein in connective tissue and neurons, which is up-regulated by hypoxia. J Biol Chem (2003) 1.54
Lessons learned from marketed and investigational prodrugs. J Med Chem (2004) 1.43
Summary workshop report: biopharmaceutics classification system--implementation challenges and extension opportunities. J Pharm Sci (2004) 1.43
Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res (2002) 1.37
Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs. AAPS J (2009) 1.37
CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metab (2010) 1.33
Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res (2006) 1.26
Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. Mol Pharm (2005) 1.21
Determination of cell survival after irradiation via clonogenic assay versus multiple MTT Assay--a comparative study. Radiat Oncol (2012) 1.20
Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase. J Biol Chem (2003) 1.19
Physiological parameters for oral delivery and in vitro testing. Mol Pharm (2010) 1.18
The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests. Mol Pharm (2006) 1.16
Transfer of lipophilic markers from PLGA and polystyrene nanoparticles to caco-2 monolayers mimics particle uptake. Pharm Res (2002) 1.12
The BCS, BDDCS, and regulatory guidances. Pharm Res (2011) 1.11
Neuroglobin, cytoglobin, and myoglobin contribute to hypoxia adaptation of the subterranean mole rat Spalax. Proc Natl Acad Sci U S A (2010) 1.10
Divergent distribution in vascular and avascular mammalian retinae links neuroglobin to cellular respiration. J Biol Chem (2005) 1.10
Pharmacokinetics of an immediate release, a controlled release and a two pulse dosage form in dogs. Eur J Pharm Biopharm (2005) 1.10
The cellular and subcellular localization of neuroglobin and cytoglobin -- a clue to their function? IUBMB Life (2005) 1.09
Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol (2009) 1.08
Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds. AAPS J (2008) 1.05
A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein. Mol Pharm (2005) 1.04
Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase. J Biol Chem (2008) 1.04
Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism. Pharm Res (2005) 1.04
Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs. Mol Cancer Ther (2005) 1.03
LRP1 mediates bidirectional transcytosis of amyloid-β across the blood-brain barrier. Neurobiol Aging (2010) 1.02
Summary workshop report: bioequivalence, biopharmaceutics classification system, and beyond. AAPS J (2008) 1.01
Influence of mechanical activation on the physical stability of salbutamol sulphate. Eur J Pharm Biopharm (2003) 1.01
Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of p-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine. Drug Metab Dispos (2009) 1.00
Localization of neuroglobin protein in the mouse brain. Neurosci Lett (2003) 1.00
Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis. Pharm Res (2003) 1.00
Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J Pharmacol Exp Ther (2003) 0.99
High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations. Mol Pharm (2010) 0.99
Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs. Mol Pharm (2009) 0.98
Comparative gene expression profiles of intestinal transporters in mice, rats and humans. Pharmacol Res (2007) 0.98
In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome. Curr Opin Drug Discov Devel (2004) 0.97
Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach. Mol Pharm (2011) 0.96
Divergent distribution of cytoglobin and neuroglobin in the murine eye. Neurosci Lett (2004) 0.95
Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine. Clin Pharmacokinet (2006) 0.95
Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells. Int J Oncol (2012) 0.95
The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone. J Pharm Sci (2010) 0.95
Differential expression pattern of the novel serine/threonine kinase, STK33, in mice and men. FEBS J (2005) 0.94
Surfactant-mediated dissolution: contributions of solubility enhancement and relatively low micelle diffusivity. J Pharm Sci (2004) 0.94
Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein. Pharm Res (2008) 0.94
Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability. Mol Pharm (2008) 0.93
Enabling the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidino oseltamivir. Mol Pharm (2010) 0.93
Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. J Pharm Sci (2002) 0.93
Stability of valacyclovir: implications for its oral bioavailability. Int J Pharm (2006) 0.92
Nucleoside ester prodrug substrate specificity of liver carboxylesterase. J Pharmacol Exp Ther (2005) 0.92
Human jejunal permeability of cyclosporin A: influence of surfactants on P-glycoprotein efflux in Caco-2 cells. Pharm Res (2003) 0.92
Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J Pharmacol Exp Ther (2009) 0.92
A novel high-throughput pepT1 transporter assay differentiates between substrates and antagonists. Mol Pharm (2004) 0.92
The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation. Mol Pharm (2010) 0.92
Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue. Mol Pharm (2013) 0.92
Enhanced absorption and growth inhibition with amino acid monoester prodrugs of floxuridine by targeting hPEPT1 transporters. Molecules (2008) 0.92
Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability. Mol Pharm (2005) 0.91
Influence of green and black tea on folic acid pharmacokinetics in healthy volunteers: potential risk of diminished folic acid bioavailability. Biopharm Drug Dispos (2008) 0.91
Neuron-specific expression of neuroglobin in mammals. Neurosci Lett (2004) 0.91
Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates. J Pharm Pharmacol (2004) 0.90
Mechanistic understanding of time-dependent oral absorption based on gastric motor activity in humans. Eur J Pharm Biopharm (2008) 0.90
The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation. Mol Pharm (2011) 0.89
Segmental-dependent membrane permeability along the intestine following oral drug administration: Evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat. Eur J Pharm Sci (2008) 0.89
Chemical and enzymatic stability of amino acid prodrugs containing methoxy, ethoxy and propylene glycol linkers. Mol Pharm (2009) 0.88
Solubilization and dissolution of insoluble weak acid, ketoprofen: effects of pH combined with surfactant. Eur J Pharm Sci (2006) 0.88
Amino acid ester prodrugs of the antiviral agent 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole as potential substrates of hPEPT1 transporter. J Med Chem (2005) 0.88
Caki-1 cells as a model system for the interaction of renally secreted drugs with OCT3. Nephron Physiol (2008) 0.88
Purely in silico BCS classification: science based quality standards for the world's drugs. Mol Pharm (2013) 0.88
Feasibility studies of utilizing disk intrinsic dissolution rate to classify drugs. Int J Pharm (2004) 0.87
In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. Pharm Res (2006) 0.87
Amino acid ester prodrugs of 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole enhance metabolic stability in vitro and in vivo. J Pharmacol Exp Ther (2005) 0.87
Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation. Mol Pharm (2009) 0.87
The fraction dose absorbed, in humans, and high jejunal human permeability relationship. Mol Pharm (2012) 0.86
Modulation of drug transport by selected flavonoids: Involvement of P-gp and OCT? Eur J Pharm Sci (2005) 0.86
Enhancing the intestinal absorption of molecules containing the polar guanidino functionality: a double-targeted prodrug approach. J Med Chem (2010) 0.86
Comparison of the permeability of metoprolol and labetalol in rat, mouse, and Caco-2 cells: use as a reference standard for BCS classification. Mol Pharm (2013) 0.86
Quasi-equilibrium analysis of the ion-pair mediated membrane transport of low-permeability drugs. J Control Release (2009) 0.85
UV exposure boosts transcutaneous immunization and improves tumor immunity: cytotoxic T-cell priming through the skin. J Invest Dermatol (2010) 0.85
Comparative gene expression of intestinal metabolizing enzymes. Biopharm Drug Dispos (2009) 0.84
Regulatory T cells and IL-10 independently counterregulate cytotoxic T lymphocyte responses induced by transcutaneous immunization. PLoS One (2011) 0.84
MRP2 mediated drug-drug interaction: indomethacin increases sulfasalazine absorption in the small intestine, potentially decreasing its colonic targeting. Int J Pharm (2009) 0.84
Enriched cereal bars are more effective in increasing plasma quercetin compared with quercetin from powder-filled hard capsules. Br J Nutr (2011) 0.84
The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J (2009) 0.83
Intestinal metabolism promotes regional differences in apical uptake of indinavir: coupled effect of P-glycoprotein and cytochrome P450 3A on indinavir membrane permeability in rat. J Pharmacol Exp Ther (2002) 0.83
The low/high BCS permeability class boundary: physicochemical comparison of metoprolol and labetalol. Mol Pharm (2014) 0.83
A fluorescent hPept1 transporter substrate for uptake screening. Pharm Res (2003) 0.83
Toward an in vivo dissolution methodology: a comparison of phosphate and bicarbonate buffers. Mol Pharm (2009) 0.83
Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans. Eur J Pharm Sci (2006) 0.83
Concentration-dependent effect of naringin on intestinal absorption of beta(1)-adrenoceptor antagonist talinolol mediated by p-glycoprotein and organic anion transporting polypeptide (Oatp). Pharm Res (2008) 0.83
In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen. Biopharm Drug Dispos (2012) 0.82
Effects of the flavonol quercetin on the bioavailability of simvastatin in pigs. Eur J Pharm Sci (2009) 0.82
Drug targeting strategies for the treatment of inflammatory bowel disease: a mechanistic update. Expert Rev Clin Immunol (2010) 0.82